Oxford, MS, and Montclair, NJ ― July 13, 2015 ― Mick Kolassa, Ph.D., Founding Partner at Medical Marketing Economics, has published an article in PM360 discussing one of the major reasons for pushback in the use of the new hepatitis C treatments: market structure. “Why Are Payers Blocking Hep C Drug Access?” appears in the June 2015 issue of the journal.
The complete article is available at the PM360 site.
For more information about PM360 as well as additional articles of interest, see the journal’s homepage.
For additional information about Mick Kolassa or Medical Marketing Economics, please contact us at 662.281.0502 or via e-mail at info@m2econ.com.
